論文

査読有り
2017年8月

Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay

LIVER INTERNATIONAL
  • Noboru Shinkai
  • ,
  • Shigeru Kusumoto
  • ,
  • Shuko Murakami
  • ,
  • Shintaro Ogawa
  • ,
  • Masaki Ri
  • ,
  • Tekeshi Matsui
  • ,
  • Akihiro Tamori
  • ,
  • Hidenori Toyoda
  • ,
  • Takashi Ishida
  • ,
  • Shinsuke Iida
  • ,
  • Yasuhito Tanaka

37
8
開始ページ
1138
終了ページ
1147
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/liv.13349
出版者・発行元
WILEY

Background & Aims: Occult hepatitis B virus (HBV) infection should be evaluated before systemic chemotherapy to prevent HBV reactivation-related hepatitis. We investigated HBV reactivation using high sensitivity HB surface antigen (HBsAg) chemiluminescent enzyme immunoassay (HBsAg-HQ) and ultra-high sensitive HBsAg assay employing a semi-automated immune complex transfer chemiluminescence enzyme technique (ICT-CLEIA).
Methods: Of 120 HBV-resolved patients with haematological malignancy receiving systemic chemotherapy from 2012 to 2015 in our hospital, 13 patients had HBV DNA reactivation (in 12/13 patients HBV DNA became quantifiable) according to HBV DNA monitoring. These patients were applied for Architect HBsAg-QT (detection limit: 50 mIU/mL), HBsAg-HQ (5 mIU/mL) and ICT-CLEIA (0.5 mIU/mL) using stored samples.
Results: When HBV DNA was firstly quantifiable by regular HBV DNA monitoring, HBsAg-QT was detected in 1/12 patients (8%), HBsAg-HQ was detected in 4/12 patients (33%) and ICT-CLEIA was detected in all 12 patients (100%), suggesting that the sensitivity of ICT-CLEIA was comparable to that of HBV DNA quantification. Interestingly, two patients were HBsAg positive by ICT-CLEIA before HBV DNA became detectable. Median difference of detectable point between HBV DNA and ICT-CLEIA was zero (range from -28 to 56 days), while median delay by HBsAg-QT or HBsAg-HQ was 52.5 days after HBV DNA became detectable. Although anti-HBs titres were high (131.9 mIU, 80.4 mIU) in two patients with escape mutations (Saa126V, Saa145R), HBsAg by ICT-CLEIA and HBV DNA were detectable concurrently.
Conclusions: ICT-CLEIA is a novel assay for HBV monitoring to prevent hepatitis caused by HBV reactivation.

Web of Science ® 被引用回数 : 14

リンク情報
DOI
https://doi.org/10.1111/liv.13349
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/27992664
Scopus
https://www.scopus.com/record/display.uri?eid=2-s2.0-85010991004&origin=inward
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000405575400008&DestApp=WOS_CPL
URL
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85010991004&origin=inward

エクスポート
BibTeX RIS